跳至主要内容
临床试验/CTRI/2012/05/002646
CTRI/2012/05/002646招募中2 期

Clinical Evaluation of Saptavimshatika Guggulu and Haridra Churna in the Management of Type II Diabetes Mellitus.

Department of AYUSH Ministry of Health Family Welfare Government of India3 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2011年1月25日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
150
试验地点
3
主要终点
• Change in Glycosylated haemoglobin (HbA1c%)

研究概览

简要总结

Aimed at scientific validation of the clinical efficacy and safety of twenty nine (29) classical Ayurvedic pharmacopoeial formulations, multicentre clinical trials have been initiated as an activity under the Ayurveda Clinical Trials (ACT) project of the Ayurvedic Pharmacopoeia Committee (APC) during August 2010 in eighteen (18) disease conditions involving fifty four (54) M.D/PhD (Ay.) research scholars in eight (08) postgraduate Ayurveda colleges across the country.

Saptavimshatika Guggulu is a poly herbal preparation containing Sunthi (Zingiber officinale), Marica (Piper nigrum), Pippali (Piper longum), Haritaki (Terminalia chebula), Bibhitaka (Terminalia belerica), Amlaki (Emblica officinalis), kustha (Saussurea lappa), Vidanga (Embelia ribes), Guduci (Tinospora cordifolia), Citraka (Plumbago zeylanica), Sati (Hedychium spicatum), Sukshma ela (Elettaria cardamomum), Pippali mula (Piper longum), Hapusa (Juniperus communis), Devdaru (Cedrus deodara), Tejovati (Zanthoxylum aromaticum), Puskara (Saussurea lappa), Cavya (Piper chaba), Rakta indravaruni (Citrullus colocynthis), Haridra (Curcuma longa), Daruharidra (Berberis aristata), Vid lavana, Saurvanchala lavana, Saindhava lavana, Yava kshara, Sarji kshara, Gaja pippali (Scindapsus officinalis) and Guggulu (Commiphora wightii).

Haridra Churna is prepared by air drying the rhizomes of Haldi (Curcuma longa).

The present study is being undertaken in three post graduate Ayurveda colleges involving the post graduate scholars who are doing the clinical trials to scientifically study and validate the clinical efficacy and safety of Saptavimshatika Guggulu and Haridra Churna- the classical Ayurvedic formulation which have been in use since ages and found to be useful in treating Type II Diabetes Mellitus and promoting the health.

The Central Council for Research in Ayurvedic Sciences (CCRAS) is the nodal organization to co-ordinate and monitor these trials. CCRAS has provided the necessary infrastructure to the participating colleges, technical inputs (including the clinical trial protocols), trial drugs and training to the researchers involved in the project.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
30.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • •Patients of either sex aged between 30 to 65 years
  • •Treatment naive patients or diagnosed patients of Type II Diabetes Mellitus taking oral hypoglycemic drugs for ≤ 6 weeks
  • •Patients having Glycosylated haemoglobin (HbA1c) ≥ 6.5%.
  • •Willing and able to participate for 16 weeks.

排除标准

  • •Patients already diagnosed to be suffering from the complications of Diabetes Mellitus viz., diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, etc.
  • •Patients suffering from brittle diabetes mellitus.
  • •Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
  • •Patient with poorly controlled Hypertension ( > 160 / 100 mm Hg)
  • •Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT > 3 times of the upper normal limit) or Renal Dysfunction (defined as S.
  • •creatinine > 1.2 mg/dl),uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or other concurrent severe disease.
  • •Pregnant / Lactating women.
  • •Patient on steroids, oral contraceptive pills or estrogen replacement therapy.
  • •Alcoholics and/or drug abusers.
  • •Patients with evidence of malignancy
  • •H/o hypersensitivity to any of the trial drugs or their ingredients.
  • •Patients who have completed participation in any other clinical trial during the past six (06) months.
  • •Any other condition which the P.I. thinks may jeopardize the study.

结局指标

主要结局

• Change in Glycosylated haemoglobin (HbA1c%)

时间窗: At Baseline, on 42nd day and on 84th day.

次要结局

  • • Change in Symptoms -Diabetes Symptoms Questionnaire (DSQ)(• Change in Blood sugar Fasting. (10-12 hrs after dinner))

研究者

发起方
Department of AYUSH Ministry of Health Family Welfare Government of India
申办方类型
Government funding agency

研究点 (3)

Loading locations...

相似试验